KUWAIT: The Kuwait Diabetes Society (KDS) signed a Memorandum of Understanding (MoU) with Sanofi for patients living with diabetes and dyslipidemia. The MoU was signed between Dr Walid Al-Dhahi, Chairman of the Kuwait Diabetes Society and Director of the Internal Medicine Department at Mubarak Al-Kabeer Hospital, and Niven Al-Khoury, General Manager of General Medicines at Sanofi KSA and Gulf MCO.

Claire Le Flecher, French Ambassador to Kuwait, was also present to witness the occasion. The partnership will enhance cardiometabolic care standards in Kuwait. Under the terms of the agreement, Sanofi will collaborate with Kuwait Diabetes Society to implement a training program aimed at enhancing the capabilities of primary care physicians in the management of diabetes and dyslipidemia. Sanofi will also support the upgrading of pharmacists’ knowledge about recent trends in Pharmacoeconomics.

Furthermore, and with the goal of empowering the patient community, Sanofi and KDS will jointly develop comprehensive awareness materials to provide patients with the tools they need to prevent and control diabetes and dyslipidemia.

Signing of the MoU.

Dr Walid Al-Dhahi: “Our cooperation with Sanofi has the potential to dramatically improve the quality of care provided to patients with diabetes, heart disease and dyslipidemia in Kuwait, bearing in mind that there are more than 803,400 diabetics in Kuwait.

The MoU covers in its scope several vital areas including the preparation and implementation of training courses and workshops for primary care doctors, pharmacists and diabetes educators with specific standards and indications for use, as well as the deployment of digital health tools to provide integrated care for patients, enabling them to achieve optimal blood sugar control. Over the years, Sanofi has played an active role in supporting Kuwait’s public health agenda, and we look forward to more fruitful cooperation between us in the time to come.”

Niven Al-Khoury: “Our collaboration with Kuwait Diabetes Society is a testament to our shared commitment to fostering a culture of care, support, and empowerment within the healthcare landscape of Kuwait.

With the rising prevalence of chronic diseases such as diabetes and dyslipidemia posing a key public health challenge in the country, Sanofi is committed to working with its partners to improve the quality of life of patients with cardiometabolic diseases. Through awareness and education, and harnessing digital solutions to empower patients, we are proud to be actively contributing to the achievement of the country’s healthcare agenda.”